Cite
HARVARD Citation
Nakai, M. et al. (2018). Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatology research. 48 (3), pp. E311-E319. [Online].